Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Treatment strategy: Role of enfuvirtide in managing treatment-limiting side effects.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Tsoukas C.
PMID: 23365593
Can J Infect Dis Med Microbiol. 2007 Jan;18:8A-9A.

Side effects can limit the options available to physicians for the treatment of HIV infection. Management of these side effects is essential, to avoid cessation of treatment. The entry inhibitor enfuvirtide can be useful as one of three active...

Cite
Tsoukas C. Treatment strategy: Role of enfuvirtide in managing treatment-limiting side effects. Can J Infect Dis Med Microbiol. 2007;18:8A-9A
Tsoukas, C. (2007). Treatment strategy: Role of enfuvirtide in managing treatment-limiting side effects. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 188A-9A.
Tsoukas, Christos. "Treatment strategy: Role of enfuvirtide in managing treatment-limiting side effects." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 18 (2007): 8A-9A.
Tsoukas C. Treatment strategy: Role of enfuvirtide in managing treatment-limiting side effects. Can J Infect Dis Med Microbiol. 2007 Jan;18:8A-9A. French. PMID: 23365593; PMCID: PMC3555490.
Copy Download .nbib Format: NLM
Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site.

Future microbiology

Cai L, Jiang S.
PMID: 19492961
Future Microbiol. 2009 Jun;4(5):507-9. doi: 10.2217/fmb.09.32.

Evaluation of: Ray N, Blackburn LA, Doms RW: HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83(7), 2989-2995 (2009). During the treatment of...

Cite
Cai L, Jiang S. Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. Future Microbiol. 2009;4(5):507-9doi: 10.2217/fmb.09.32.
Cai, L., & Jiang, S. (2009). Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. Future microbiology, 4(5), 507-9. https://doi.org/10.2217/fmb.09.32
Cai, Lifeng, and Jiang, Shibo. "Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site." Future microbiology vol. 4,5 (2009): 507-9. doi: https://doi.org/10.2217/fmb.09.32
Cai L, Jiang S. Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. Future Microbiol. 2009 Jun;4(5):507-9. doi: 10.2217/fmb.09.32. PMID: 19492961.
Copy Download .nbib Format: NLM
Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay.

Avicenna journal of medical biotechnology

Sardari S, Azadmanesh K, Mahboudi F, Davood A, Vahabpour R, Zabihollahi R, Gomari H.
PMID: 23799176
Avicenna J Med Biotechnol. 2013 Apr;5(2):78-86.

BACKGROUND: Gp41 of HIV (Human Immunodeficiency Virus) is a protein that mediates fusion between viral and cellular membranes. The agent, T-20, which has been approved for HIV inhibition, can restrain Gp41 function in the fusion process; nevertheless, it has...

Cite
Sardari S, Azadmanesh K, Mahboudi F, et al. Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol. 2013;5(2):78-86
Sardari, S., Azadmanesh, K., Mahboudi, F., Davood, A., Vahabpour, R., Zabihollahi, R., & Gomari, H. (2013). Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna journal of medical biotechnology, 5(2), 78-86.
Sardari, Soroush, et al. "Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay." Avicenna journal of medical biotechnology vol. 5,2 (2013): 78-86.
Sardari S, Azadmanesh K, Mahboudi F, Davood A, Vahabpour R, Zabihollahi R, Gomari H. Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol. 2013 Apr;5(2):78-86. PMID: 23799176; PMCID: PMC3689560.
Copy Download .nbib Format: NLM
Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies.

The open virology journal

Yee M, Konopka K, Balzarini J, Düzgüneş N.
PMID: 21660189
Open Virol J. 2011;5:44-51. doi: 10.2174/1874357901105010044. Epub 2011 May 12.

BACKGROUND: Broadly cross-reactive, neutralizing human monoclonal antibodies, including 2F5, 2G12, 4E10 and IgG1 b12, can inhibit HIV-1 infection in vitro at very low concentrations. We examined the ability of these antibodies to inhibit cell-cell fusion between Clone69TRevEnv cells induced...

Cite
Yee M, Konopka K, Balzarini J, et al. Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies. Open Virol J. 2011;5:44-51doi: 10.2174/1874357901105010044.
Yee, M., Konopka, K., Balzarini, J., & Düzgüneş, N. (2011). Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies. The open virology journal, 544-51. https://doi.org/10.2174/1874357901105010044
Yee, Michael, et al. "Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies." The open virology journal vol. 5 (2011): 44-51. doi: https://doi.org/10.2174/1874357901105010044
Yee M, Konopka K, Balzarini J, Düzgüneş N. Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies. Open Virol J. 2011;5:44-51. doi: 10.2174/1874357901105010044. Epub 2011 May 12. PMID: 21660189; PMCID: PMC3109660.
Copy Download .nbib Format: NLM
Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Loutfy M, Kovacs C.
PMID: 23365590
Can J Infect Dis Med Microbiol. 2007 Jan;18:10A-1A.

For full HIV virological suppression, three fully active antiretroviral agents are required. New drug classes should be included to ensure that agents are fully active. The addition of enfuvirtide and efavirenz to the present patient's new antiretroviral regimen ensured...

Cite
Loutfy M, Kovacs C. Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe. Can J Infect Dis Med Microbiol. 2007;18:10A-1A
Loutfy, M., & Kovacs, C. (2007). Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 1810A-1A.
Loutfy, Mona, and Kovacs, Colin. "Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 18 (2007): 10A-1A.
Loutfy M, Kovacs C. Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe. Can J Infect Dis Med Microbiol. 2007 Jan;18:10A-1A. French. PMID: 23365590; PMCID: PMC3555493.
Copy Download .nbib Format: NLM
Generation of a long-acting fusion inhibitor against HIV-1.

MedChemComm

Guo Y, Zhou PP, Zhang SY, Fan XW, Dou YW, Shi XL.
PMID: 30109011
Medchemcomm. 2018 Jun 06;9(7):1226-1231. doi: 10.1039/c8md00124c. eCollection 2018 Jul 01.

AIDS has evolved from a fatal infectious disease to a manageable chronic disease under the treatment of anti-AIDS medications. HIV fusion inhibitors with high activity, low side effects and strong selectivity are promising drugs against HIV. Only one fusion...

Cite
Guo Y, Zhou PP, Zhang SY, et al. Generation of a long-acting fusion inhibitor against HIV-1. Medchemcomm. 2018;9(7):1226-1231doi: 10.1039/c8md00124c.
Guo, Y., Zhou, P. P., Zhang, S. Y., Fan, X. W., Dou, Y. W., & Shi, X. L. (2018). Generation of a long-acting fusion inhibitor against HIV-1. MedChemComm, 9(7), 1226-1231. https://doi.org/10.1039/c8md00124c
Guo, Ye, et al. "Generation of a long-acting fusion inhibitor against HIV-1." MedChemComm vol. 9,7 (2018): 1226-1231. doi: https://doi.org/10.1039/c8md00124c
Guo Y, Zhou PP, Zhang SY, Fan XW, Dou YW, Shi XL. Generation of a long-acting fusion inhibitor against HIV-1. Medchemcomm. 2018 Jun 06;9(7):1226-1231. doi: 10.1039/c8md00124c. eCollection 2018 Jul 01. PMID: 30109011; PMCID: PMC6071707.
Copy Download .nbib Format: NLM
New fusion inhibitor drug stops HIV from spreading.

AIDS policy & law

[No authors listed]
PMID: 14686290
AIDS Policy Law. 2002 Aug 02;17(14):9.

No abstract available.

Cite
New fusion inhibitor drug stops HIV from spreading. AIDS Policy Law. 2002;17(14):9
(2002). New fusion inhibitor drug stops HIV from spreading. AIDS policy & law, 17(14), 9.
"New fusion inhibitor drug stops HIV from spreading." AIDS policy & law vol. 17,14 (2002): 9.
New fusion inhibitor drug stops HIV from spreading. AIDS Policy Law. 2002 Aug 02;17(14):9. PMID: 14686290.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries